BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 20869823)

  • 1. Risk-reducing salpingo-oophorectomy for BRCA mutation carriers.
    Haldar K; Crawford R
    Maturitas; 2010 Nov; 67(3):290. PubMed ID: 20869823
    [No Abstract]   [Full Text] [Related]  

  • 2. Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation.
    Kauff ND; Satagopan JM; Robson ME; Scheuer L; Hensley M; Hudis CA; Ellis NA; Boyd J; Borgen PI; Barakat RR; Norton L; Castiel M; Nafa K; Offit K
    N Engl J Med; 2002 May; 346(21):1609-15. PubMed ID: 12023992
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Short-term surgical outcome and safety of risk reducing salpingo-oophorectomy in BRCA1/2 mutation carriers.
    Kenkhuis MJ; de Bock GH; Elferink PO; Arts HJ; Oosterwijk JC; Jansen L; Mourits MJ
    Maturitas; 2010 Jul; 66(3):310-4. PubMed ID: 20409655
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oral contraceptives, salpingo-oophorectomy and hormone replacement therapy in BRCA1-2 mutation carriers.
    Biglia N; Mariani L; Ponzone R; Sismondi P
    Maturitas; 2008 Jun; 60(2):71-7. PubMed ID: 18472232
    [No Abstract]   [Full Text] [Related]  

  • 5. Prophylactic oophorectomy to reduce the risk of ovarian and breast cancer in carriers of BRCA mutations.
    Haber D
    N Engl J Med; 2002 May; 346(21):1660-2. PubMed ID: 12024000
    [No Abstract]   [Full Text] [Related]  

  • 6. CA125 screening after risk-reducing salpingo-oophorectomy: are the titers too high, or is it all just too much?
    Bradford LS; Schorge JO
    Menopause; 2011 Feb; 18(2):123-4. PubMed ID: 21191312
    [No Abstract]   [Full Text] [Related]  

  • 7. Risk-reducing salpingo-oophorectomy in BRCA1 and BRCA2 mutation carriers.
    Rhiem K; Foth D; Wappenschmidt B; Gevensleben H; Büttner R; Ulrich U; Schmutzler RK
    Arch Gynecol Obstet; 2011 Mar; 283(3):623-7. PubMed ID: 20428881
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Surveillance of survivors: follow-up after risk-reducing salpingo-oophorectomy in BRCA 1/2 mutation carriers.
    Chapman JS; Powell CB; McLennan J; Crawford B; Mak J; Stewart N; Chen LM
    Gynecol Oncol; 2011 Aug; 122(2):339-43. PubMed ID: 21531449
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oophorectomy in carriers of BRCA mutations.
    Whitfield GA
    N Engl J Med; 2002 Sep; 347(13):1037-40; author reply 1037-40. PubMed ID: 12353513
    [No Abstract]   [Full Text] [Related]  

  • 10. Predictors of occult neoplasia in women undergoing risk-reducing salpingo-oophorectomy.
    Lamb JD; Garcia RL; Goff BA; Paley PJ; Swisher EM
    Am J Obstet Gynecol; 2006 Jun; 194(6):1702-9. PubMed ID: 16731090
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Outcome of risk-reducing salpingo-oophorectomy in BRCA carriers and women of unknown mutation status.
    Manchanda R; Abdelraheim A; Johnson M; Rosenthal AN; Benjamin E; Brunell C; Burnell M; Side L; Gessler S; Saridogan E; Oram D; Jacobs I; Menon U
    BJOG; 2011 Jun; 118(7):814-24. PubMed ID: 21392246
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Surgical risk reduction: prophylactic salpingo-oophorectomy and prophylactic mastectomy.
    Dowdy SC; Stefanek M; Hartmann LC
    Am J Obstet Gynecol; 2004 Oct; 191(4):1113-23. PubMed ID: 15507929
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prophylactic oophorectomy in women at increased cancer risk.
    Domchek SM; Rebbeck TR
    Curr Opin Obstet Gynecol; 2007 Feb; 19(1):27-30. PubMed ID: 17218848
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ovarian pathology in risk-reducing salpingo-oophorectomies from women with BRCA mutations, emphasizing the differential diagnosis of occult primary and metastatic carcinoma.
    Rabban JT; Barnes M; Chen LM; Powell CB; Crawford B; Zaloudek CJ
    Am J Surg Pathol; 2009 Aug; 33(8):1125-36. PubMed ID: 19440148
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gynaecologic challenging issues in the management of BRCA mutation carriers: oral contraceptives, prophylactic salpingo-oophorectomy and hormone replacement therapy.
    Gadducci A; Biglia N; Cosio S; Sismondi P; Genazzani AR
    Gynecol Endocrinol; 2010 Aug; 26(8):568-77. PubMed ID: 20632911
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk-reducing salpingo-oophorectomy in patients with germline mutations in BRCA1 or BRCA2.
    Kauff ND; Barakat RR
    J Clin Oncol; 2007 Jul; 25(20):2921-7. PubMed ID: 17617523
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oophorectomy in carriers of BRCA mutations.
    Anderson WF; Brawley OW; Chang S
    N Engl J Med; 2002 Sep; 347(13):1037-40; author reply 1037-40. PubMed ID: 12353512
    [No Abstract]   [Full Text] [Related]  

  • 18. Prophylactic salpingo-oophorectomy in a series of 89 women carrying a BRCA1 or a BRCA2 mutation.
    Mahajan NN
    Cancer; 2007 Dec; 110(12):2819; author reply 2819-20. PubMed ID: 17969078
    [No Abstract]   [Full Text] [Related]  

  • 19. Occult ovarian cancer at the time of risk-reducing salpingo-oophorectomy.
    Powell CB
    Gynecol Oncol; 2006 Jan; 100(1):1-2. PubMed ID: 16368438
    [No Abstract]   [Full Text] [Related]  

  • 20. Risk-reducing salpingo-oophorectomy in BRCA mutation carriers: role of serial sectioning in the detection of occult malignancy.
    Powell CB; Kenley E; Chen LM; Crawford B; McLennan J; Zaloudek C; Komaromy M; Beattie M; Ziegler J
    J Clin Oncol; 2005 Jan; 23(1):127-32. PubMed ID: 15625367
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.